JP2022512875A5 - - Google Patents

Info

Publication number
JP2022512875A5
JP2022512875A5 JP2021523670A JP2021523670A JP2022512875A5 JP 2022512875 A5 JP2022512875 A5 JP 2022512875A5 JP 2021523670 A JP2021523670 A JP 2021523670A JP 2021523670 A JP2021523670 A JP 2021523670A JP 2022512875 A5 JP2022512875 A5 JP 2022512875A5
Authority
JP
Japan
Prior art keywords
heavy chain
seq
sequence shown
region
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021523670A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512875A (ja
JP7527281B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/080445 external-priority patent/WO2020094744A1/en
Publication of JP2022512875A publication Critical patent/JP2022512875A/ja
Publication of JP2022512875A5 publication Critical patent/JP2022512875A5/ja
Priority to JP2024117394A priority Critical patent/JP2024138555A/ja
Application granted granted Critical
Publication of JP7527281B2 publication Critical patent/JP7527281B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021523670A 2018-11-06 2019-11-06 抗体製剤 Active JP7527281B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024117394A JP2024138555A (ja) 2018-11-06 2024-07-23 抗体製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2018080369 2018-11-06
EPPCT/EP2018/080369 2018-11-06
PCT/EP2019/080445 WO2020094744A1 (en) 2018-11-06 2019-11-06 Antibody formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024117394A Division JP2024138555A (ja) 2018-11-06 2024-07-23 抗体製剤

Publications (3)

Publication Number Publication Date
JP2022512875A JP2022512875A (ja) 2022-02-07
JP2022512875A5 true JP2022512875A5 (cg-RX-API-DMAC10.html) 2022-11-14
JP7527281B2 JP7527281B2 (ja) 2024-08-02

Family

ID=68393014

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021523670A Active JP7527281B2 (ja) 2018-11-06 2019-11-06 抗体製剤
JP2024117394A Pending JP2024138555A (ja) 2018-11-06 2024-07-23 抗体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024117394A Pending JP2024138555A (ja) 2018-11-06 2024-07-23 抗体製剤

Country Status (13)

Country Link
US (1) US20210369842A1 (cg-RX-API-DMAC10.html)
EP (1) EP3877409A1 (cg-RX-API-DMAC10.html)
JP (2) JP7527281B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210124959A (cg-RX-API-DMAC10.html)
CN (2) CN113454111A (cg-RX-API-DMAC10.html)
AU (2) AU2019375014B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021008774A2 (cg-RX-API-DMAC10.html)
CA (1) CA3118789A1 (cg-RX-API-DMAC10.html)
IL (1) IL282813A (cg-RX-API-DMAC10.html)
MA (1) MA54139A (cg-RX-API-DMAC10.html)
MX (1) MX2021005085A (cg-RX-API-DMAC10.html)
SG (1) SG11202104300PA (cg-RX-API-DMAC10.html)
WO (1) WO2020094744A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250020679A (ko) 2017-08-04 2025-02-11 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
WO2021156326A1 (en) * 2020-02-04 2021-08-12 Genmab A/S Antibodies for use in therapy
CN117582496A (zh) * 2020-12-18 2024-02-23 美勒斯公司 抗体组合物
KR20240004949A (ko) * 2021-05-07 2024-01-11 젠맵 에이/에스 B7h4 및 cd3에 결합하는 이중특이적 항체를 포함하는 제약 조성물
WO2023057534A1 (en) * 2021-10-06 2023-04-13 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination
WO2024008032A1 (en) * 2022-07-06 2024-01-11 Beijing Hanmi Pharmaceutical Co., Ltd. Formulations for anti-pd-l1/anti-4-1bb bispecific antibodies
WO2026145640A1 (zh) * 2025-01-03 2026-07-09 长春金赛药业有限责任公司 一种抗IL-1β抗体的药物组合物及其用途

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
FR2814691B1 (fr) 2000-09-29 2003-10-03 Commissariat Energie Atomique Procede et dispositif de degraissage
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
CA2531118C (en) 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディ及びその使用
AU2010229705A1 (en) 2009-03-27 2011-10-20 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
IN2014CN03887A (cg-RX-API-DMAC10.html) 2011-10-27 2015-10-16 Genmab As
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
PL3489254T3 (pl) 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
CN111499755A (zh) 2012-08-03 2020-08-07 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
DK3049441T3 (da) 2013-09-27 2020-02-03 Hoffmann La Roche Anti-PDL1-antistofformuleringer
CN106459165B (zh) 2014-04-01 2021-04-20 拜恩科技细胞&基因治疗有限公司 密封蛋白-6特异性免疫受体和t细胞表位
SG11201704056XA (en) * 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
EP3233907B1 (en) 2014-12-19 2021-03-03 Genmab A/S Rodent bispecific heterodimeric proteins
SMT201900702T1 (it) 2015-01-08 2020-01-14 Genmab As Agenti agonistici leganti il recettore del tnf
HRP20201334T1 (hr) 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
BR112019000512A2 (pt) * 2016-07-14 2019-04-24 Genmab A/S anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
EP3515951B1 (en) 2016-09-23 2024-02-28 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
WO2018098370A1 (en) 2016-11-23 2018-05-31 Immunoah Therapeutics, Inc. 4-1bb binding proteins and uses thereof
LT3592769T (lt) * 2017-03-09 2024-08-26 Genmab A/S Antikūnai, atpažįstantys pd-l1

Similar Documents

Publication Publication Date Title
US12622954B2 (en) Anti-ICOS agonist antibodies and uses thereof
JP7847630B2 (ja) Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質
EP3334431B1 (en) 5-bromo-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer
JP2020500006A (ja) 抗lag−3抗体および組成物
BR112021005868A2 (pt) Anticorpos anti-hla-g, composições compreendendo anticorpos anti-hla-g e métodos de uso de anticorpos anti-hla-g
TW201706305A (zh) 具有增強之激動劑活性之針對cd40的抗體
KR20160131061A (ko) 항-mcam 항체 및 관련된 사용 방법
BR112020022371A2 (pt) anticorpos de alta afinidade para pd-1 e lag-3 e proteínas de ligação biespecífica produzidas a partir dos mesmos
JP2021531821A (ja) 効率的に発現されるegfr及びpd−l1二重特異性結合タンパク質
CN111788227B (zh) 抗cd40抗体及其用途
TW202448953A (zh) 用於腫瘤及轉移之治療的基於沉默抗體的抗met建構物
CN116322767A (zh) 改善与静脉内施用有关的抗体耐受性
JP6964113B2 (ja) がんの処置に使用するための5−ブロモ−2,6−ジ−(1h−ピラゾール−1−イル)ピリミジン−4−アミン
HK40087544A (zh) 改善与静脉内施用有关的抗体耐受性
NZ791361B2 (en) Engineered anti-il-2 antibodies
BR122025002178A2 (pt) Anticorpos para cd3 e bcma, e proteínas de ligação biespecíficas feitas a partir dos mesmos
EA041306B1 (ru) Агонистические антитела против icos и их применение
EA041917B1 (ru) Антитела с низкой иммуногенностью и их применения